← Back to all stories
Promising New Cancer Vaccine Shows Durable Immune Response in High-Risk Patients
Photo: Mufid Majnun / Unsplash
Researchers at Johns Hopkins have successfully tested an experimental drug that safely triggers a lasting immune response against one of the most common genetic drivers of pancreatic cancer. This breakthrough offers a hopeful new path for preventing one of the most challenging forms of cancer in individuals at high risk.
Researchers at Johns Hopkins have successfully tested an experimental drug that safely triggers a lasting immune response against one of the most common genetic drivers of pancreatic cancer. This breakthrough offers a hopeful new path for preventing one of the most challenging forms of cancer in individuals at high risk.